LRRK2 and Parkinson disease: Specifically, Hockey and colleagues found that fibroblasts from LRRK2 PD patients carrying the G2019S mutation (that enhances kinase activity) had exaggerated TPC2 Ca2+ release, impacting lysosome morphology and function [43] (Fig. 1).